The UK Medicines and Healthcare Products Regulatory Agency has strengthened warnings for GLP-1 receptor agonists and GLP-1/GIP dual agonists. These warnings include an association with fatal events. The article also mentions the US Department of Justice (DOJ) lawsuit against the medical school. The third topic is genes and longevity. In relation to GLP-1 agonists, studies show a 13% reduction in cardiovascular mortality, a 16% reduction in nonfatal strokes, and a 9% reduction in nonfatal myocardial infarctions. The treatment resulted in a 10% decrease in the risk of heart failure and a 17% reduction in the composite renal index. Side effects include nausea, vomiting, diarrhea, constipation, pancreatitis, and kidney problems.